Immunogenetics Laboratory, Abel Salazar Institute of Biomedical Sciences (ICBAS), University of Porto (UP), Porto, Portugal; Unit for Multidisciplinary Research in Biomedicine (UMIB), Abel Salazar Institute of Biomedical Sciences (ICBAS), University of Porto (UP), Porto, Portugal.
Immunogenetics Laboratory, Abel Salazar Institute of Biomedical Sciences (ICBAS), University of Porto (UP), Porto, Portugal.
J Steroid Biochem Mol Biol. 2018 Jun;180:137-141. doi: 10.1016/j.jsbmb.2017.09.016. Epub 2017 Sep 22.
Increasing evidence has shown that individuals with Multiple Sclerosis (MS) have lower 25-hydroxyvitamin D [25(OH)D] levels compared to healthy controls. There is no information regarding 25(OH)D levels and MS in Portugal. Therefore the aim of the current study was to examine the levels of 25(OH)D in a group of patients with MS and in healthy matched controls, as well as the association of 25(OH)D levels with disease course, disability and severity. A group of 244 unrelated Portuguese patients, with a definitive diagnosis of MS, and 198 ethnically matched healthy controls were included in the study. A sub-group of patients with recent disease onset was included. Serum 25(OH)D was measured using an electrochemiluminescence binding assay. The mean serum level of 25(OH)D in patients with MS was 39.9±22.0 nmol/L, which was significantly lower (p<0.0001) than those in healthy controls, 55.4±23.4 nmol/L. There was a negative correlation between 25(OH)D levels and EDSS (r=-0.293, p<0.0001) and MSSS scores (r=-0.293, p<0.0001). In multiple logistic regression analysis adjusted for age, gender, disease form, EDSS, disease duration and MSSS, 25(OH)D levels were independently associated with EDSS (p=0.004) and disease duration (p=0.016), and with MSSS (p=0.001). In accordance with the majority of the literature, low serum 25(OH)D levels were associated with susceptibility and disability in MS patients from Portugal. Lower serum 25(OH)D levels were also found in patients with a recent disease onset, supporting vitamin D levels as a risk factor for MS.
越来越多的证据表明，与健康对照组相比，多发性硬化症（MS）患者的 25-羟维生素 D [25（OH）D]水平较低。目前葡萄牙尚无关于 25（OH）D 水平与 MS 的信息。因此，本研究旨在检查一组 MS 患者和健康匹配对照者的 25（OH）D 水平，以及 25（OH）D 水平与疾病病程、残疾和严重程度的相关性。研究纳入了 244 名无亲缘关系的葡萄牙 MS 患者和 198 名种族匹配的健康对照者。还纳入了一组近期发病的患者。使用电化学发光结合测定法测定血清 25（OH）D。MS 患者的血清 25（OH）D 平均水平为 39.9±22.0 nmol/L，显著低于健康对照组（55.4±23.4 nmol/L）（p<0.0001）。25（OH）D 水平与 EDSS（r=-0.293，p<0.0001）和 MSSS 评分（r=-0.293，p<0.0001）呈负相关。在校正年龄、性别、疾病形式、EDSS、疾病持续时间和 MSSS 后进行多因素逻辑回归分析，25（OH）D 水平与 EDSS（p=0.004）和疾病持续时间（p=0.016）以及 MSSS（p=0.001）独立相关。与大多数文献一致，葡萄牙 MS 患者血清 25（OH）D 水平较低与易感性和残疾有关。最近发病的患者血清 25（OH）D 水平也较低，支持维生素 D 水平是 MS 的危险因素。
